Skip to main content

Advertisement

SpringerLink
Log in

Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Preclinical studies have demonstrated a synergistic effect with the angiogenesis inhibitor TNP-470 and several cytotoxic agents. A recent clinical trial with the combination of paclitaxel and TNP-470 has shown promising effects. The present study was designed to determine the toxicity and pharmacokinetics of carboplatin in combination with TNP-470 in comparison with the doublet regimen of paclitaxel and carboplatin in patients with solid tumors.

Experimental design

Enrolled in the study were 17 patients with lung (11), head/neck (3), sarcoma (2) and thymoma (1). The patients received intravenous paclitaxel and carboplatin on day 1 followed by TNP-470 (60 mg/m2 i.v. over 1 h administered thrice weekly on Monday, Wednesday, and Friday). Each cycle of therapy consisted of 3 weeks. The initial cohort of three patients received carboplatin at AUC 5 mg/ml×min. No dose-limiting toxic effects occurred, thus the subsequent cohort received carboplatin at AUC 6 mg/ml×min. In addition to toxicity, the pharmacokinetics of carboplatin were evaluated, and tumor response and patient survival rates were assessed.

Results

The administered regimen of paclitaxel (225 mg/m2 i.v. over 3 h) and carboplatin (AUC 6 mg/ml×min i.v. over 1 h) on day 1 followed by TNP-470 (60 mg/m2 i.v. over 1 h administered thrice weekly on Monday, Wednesday, and Friday) was defined as both the maximum tolerated and optimal dose. Hematological toxic effects were similar to those expected with the chemotherapy doublet. All neurocognitive impairments were graded as mild to moderate and reversed after discontinuation of TNP-470 administration. No alterations in the pharmacokinetic disposition of carboplatin were noted. Overall, the median survival duration was 297 days. Four patients (24%) had a partial response, and eight (47%) had stable disease.

Conclusions

The combination of TNP-470, paclitaxel, and carboplatin is a reasonably well tolerated regimen. Further randomized studies of TNP-470 with this doublet regimen are now warranted for non-small-cell lung carcinoma and other solid tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Antoine N, Greimers R, De Roanne C, Kusaka M, Heinen E, Simar LJ, Castronovo V (1994) AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res 54:2073–2076

    CAS  PubMed  Google Scholar 

  2. Baidas S, Bhargava P, Isaacs C, Rizvi N, Trocky N, Pipkin T, Hayes D, Marshall J (2000) Phase I study of the combination of TNP-470 and paclitaxel in patients with advanced cancer. Proc Am Soc Clin Oncol (abstract 800)

  3. Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, Figuera M, Philipps K, Ong VS, Kato A, Hawkins MJ (1999) A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 5:1989–1995

    CAS  PubMed  Google Scholar 

  4. Bhargava P, Rizvi N, Baidas S, Figueira M, Malerczyk C, Dordal M, Marshall J, Anton, Wellstein A (2000) Phase I study and assessment of bioactivity of 120-hour infusion of TNP-470 in patients with advanced cancer. Proc Am Soc Clin Oncol (abstract 681)

  5. Bissett D, O’Byrne K, von Pawel J, Mercier R, Price A, Nicolson M, Shepherd F, Mazabel E, Penning C, Zhang MH, Collier MA (2002) Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat (P) in combination with gemcitabine (G) and cisplatin (C) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21:296a (abstract 1183)

    Google Scholar 

  6. Blumenschein GR Jr, Fossella FV, Pisters KM, Khuri FR, Lu C, Kies MS, Glisson BS, Zinner R, Crane E, Schaerer R, Dordal M, Goodin T, Hong WK, Herbst RS (2002) A phase I study of TNP-470 continuous infusion alone or in combination with paclitaxel and carboplatin in adult patients with NSCLC and other solid tumors. Proc Am Soc Clin Oncol 21:314a (abstract 1254)

    Google Scholar 

  7. Castronovo V, Belotti D (1996) TNP-470 (AGM-1470): mechanism of action and early clinical development. Eur J Cancer 32A:2520–2527

    CAS  PubMed  Google Scholar 

  8. Fountzilas G, Dimopoulos AM, Papadimitriou C, Kalogera-Fountzila A, Aravantinos G, Bafaloukos D, Athanassiades A, Nicolaides C, Keramopoulos A, Pavlidis N, Kosmidis P, Skarlos D (1998) First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 9:1031–1034

    Article  CAS  PubMed  Google Scholar 

  9. Gadducci A, Brunetti I, Cosio S, Giannessi PG, Genazzani AR, Conte P (1997) Platinum compounds and paclitaxel in advanced epithelial ovarian cancer. Anticancer Res 17(6D):4703–4708

    CAS  PubMed  Google Scholar 

  10. Herbst RS, Takeuchi H, Teicher BA (1998) Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small cell lung and breast carcinoma models. Cancer Chemother Pharmacol 41:497–504

    CAS  PubMed  Google Scholar 

  11. Herbst RS, Madden TL, Tran HT, Blumenschein GR Jr, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA Jr, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK (2002) Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small cell lung cancer. J Clin Oncol 20:4440–4447

    Article  CAS  PubMed  Google Scholar 

  12. Herbst RS, Hammond LA, Carbone DP, Tran HT, Holroyd KJ, Desai A, Williams JI, Bekele BN, Hait H, Allgood V, Solomon S, Schiller JH (2003) A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 9:4108–4115

    CAS  PubMed  Google Scholar 

  13. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348:555–557

    CAS  PubMed  Google Scholar 

  14. Isobe N, Uozumi T, Kurisu K, Kawamoto K (1996) Experimental studies of the antitumor effect of TNP-470 on malignant brain tumors. Antitumor effects of TNP-470 on a human medulloblastoma xenograft line. Neuropediatrics 27:136–142

    CAS  PubMed  Google Scholar 

  15. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457–481

    Google Scholar 

  16. Kudelka AP, Levy T, Verschraegen CF, Edwards CL, Piamsomboon S, Termrungruanglert W, Freedman RS, Kaplan AL, Kieback DG, Meyers CA, Jaeckle KA, Loyer E, Steger M, Mante R, Mavligit G, Killian A, Tang RA, Gutterman JU, Kavanagh JJ (1997) A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 3:1501–1515

    CAS  PubMed  Google Scholar 

  17. Kudelka AP, Verschraegen CF, Loyer E (1998) Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N Engl J Med 338:991–992

    Article  CAS  PubMed  Google Scholar 

  18. Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, Gutterman JU (2001) Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 7:1198–1203

    CAS  PubMed  Google Scholar 

  19. Madden T, Sunderland M, Santana VM, Rodman JH (1992) The pharmacokinetics of high-dose carboplatin in pediatric patients with cancer. Clin Pharmacol Ther 51:701–707

    CAS  PubMed  Google Scholar 

  20. Mininberg ED, Herbst RS, Henderson T, Kim E, Hong WK, Mass R, Novotny W, Garcia B, Johnson D, Sandler A (2003) Phase I/II study of the recombinant humanized monoclonal anti-VEGF antibody bevacizumab and the EGFR-TK inhibitor erlotinib in patients with recurrent non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 22:627 (abstract 2521)

    Google Scholar 

  21. Offedile R, Walton T, Lee M, Stiles A, Nguyen M (1999) Regression of metastatic breast cancer in patients treated with the anti-angiogenic drug TNP-470. Tumori 85:51–53

    CAS  PubMed  Google Scholar 

  22. Rigas JR, Denham CA, Rinaldi DA, Moore TD, Smith JW, Winston RD, Sridhar KS, Valera SZB, Humphrey R, Sorensen JM (2003) Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor (MMPI), BAY12-9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer. Proc Am Soc Oncol 22:628 (abstract 2525)

    Google Scholar 

  23. Satchi-Fainaro R, Corfas G, Tran H, Folkman J (2004) Tumor angiogenesis as a novel target for polymer therapeutics. In: Proceedings of the meeting Angiogenesis: Novel Basic Science Insights and Human Therapy. Keystone Symposia, Silverthorne, CO, p 84

  24. Satchi-Fainaro R, Puder M, Davies J, Tran HT, Greene AK, Corfas G, Folkman J (2004) Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 10:255–261

    Article  CAS  PubMed  Google Scholar 

  25. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

    Google Scholar 

  26. Sin M, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM (1997) The antiangiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A 94:6099–6103

    Google Scholar 

  27. Smylie M, Mercier R, Aboulafia D, Tucker R, Bonomi P, Collier M, Keller MR, Stuart-Smith J, Knowles M, Clendeninn NJ, Shepherd F (2001) Phase III study of the matrix metalloproteinase (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 20:307a (abstract 1226)

    Google Scholar 

  28. Sridhar SS, Shepherd FA (2003) Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 42:S81–S91

    Article  PubMed  Google Scholar 

  29. Takamiya Y, Brem H, Ojeifo J, Mineta T, Martuza R (1994) AGM-1470 inhibits growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 34:869–875

    CAS  PubMed  Google Scholar 

  30. Teicher BA, Holden SA, Ara G, Sotomayor EA, Huang ZD, Chen YN, Brem H (1994) Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents. Int J Cancer 57:920–925

    CAS  PubMed  Google Scholar 

  31. Teicher BA, Holden SA, Dupuis NP, Kakeji Y, Ikebe M, Emi Y, Goff D (1995) Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res Treat 36:227–236

    CAS  PubMed  Google Scholar 

  32. Teicher BA, Holden SA, Ara G, Korbut T, Menon K (1996) Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother Pharmacol 38:169–177

    CAS  PubMed  Google Scholar 

  33. Turk BE, Griffith EC, Wolf S, Biemann K, Chang YH, Liu JO (1999) Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells. Chem Biol 6:823–833

    Article  CAS  PubMed  Google Scholar 

  34. Whalen CT, Hanson, Putzer KJ, Mayer MD, Mulford ML (2002) Assay of TNP-470 and its two major metabolites in human plasma by high performance liquid chromatography-mass spectrometry. J Chromatogr Sci 49:214–218

    Google Scholar 

Download references

Acknowledgement

This research was supported by a grant from TAP Pharmaceutical Products, Inc., an ASCO Career Development Award, and an M. D. Anderson Cancer Center Physician Scientist Program Award to Dr. Roy S. Herbst.

Author information

Authors and Affiliations

  1. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 432, Houston, TX 77030, USA

    Hai T. Tran, George R. Blumenschein Jr., Charles Lu, Vali Papadimitrakopoulou, Frank V. Fossella, Ralph Zinner & Roy S. Herbst

  2. Department of Pharmaceutical Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

    Hai T. Tran & Timothy Madden

  3. Department of Clinical Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

    Christina A. Meyers, Lori G. Smythe & Vinay K. Puduvalli

  4. Department of Diagnostic Radiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

    Reggie Munden & Mylene Truong

Authors
  1. Hai T. Tran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George R. Blumenschein Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charles Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christina A. Meyers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vali Papadimitrakopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Frank V. Fossella
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ralph Zinner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Timothy Madden
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Lori G. Smythe
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Vinay K. Puduvalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Reggie Munden
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Mylene Truong
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Roy S. Herbst
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hai T. Tran.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tran, H.T., Blumenschein, G.R., Lu, C. et al. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 54, 308–314 (2004). https://doi.org/10.1007/s00280-004-0816-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-004-0816-z

Keywords

Search

Navigation